Table 3.
Patients’ characteristics according to whether they underwent surgery
| Variable | Primary RT (n = 20) | Adjuvant RT (n = 21) | p-value |
|---|---|---|---|
| Age (yr) | |||
| <65 | 6 (30.0) | 7 (33.3) | 0.819 |
| ≥65 | 14 (70.0) | 14 (66.7) | |
| Sex | |||
| Male | 10 (50.0) | 7 (33.3) | 0.279 |
| Female | 10 (50.0) | 14 (66.7) | |
| ECOG PS | |||
| 0–1 | 13 (65.0) | 15 (71.4) | 0.658 |
| 2–4 | 7 (35.0) | 6 (28.6) | |
| Stage | |||
| IVA | 1 (5.0) | 4 (19.0) | 0.002 |
| IVB | 6 (30.0) | 14 (66.7) | |
| IVC | 13 (65.0) | 3 (14.3) | |
| Chemotherapy | |||
| Yes | 15 (25.0) | 16 (76.2) | 0.999 |
| No | 5 (75.0) | 5 (23.8) | |
| RT modality | |||
| IMRT | 11 (55.0) | 17 (81.0) | 0.074 |
| 3D-CRT | 9 (45.0) | 4 (19.0) | |
| EQD210 dose (Gy) | |||
| <62.0 | 6 (30.0) | 7 (33.3) | 0.999 |
| ≥62.0 | 14 (70.0) | 14 (66.7) |
Values are presented as number (%).
RT, radiation therapy; ECOG PS, Eastern Cooperative Oncology Group performance score; IMRT, intensity-modulated radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy.